Geron Updates on 50% Enrollment in the Phase 3 IMpactMF Clinical Trial Evaluating Imetelstat in Patients with Relapsed/Refractory Myelofibrosis

Press/Media

Period14 Dec 2023

Media coverage

1

Media coverage

  • TitleGeron Updates on 50% Enrollment in the Phase 3 IMpactMF Clinical Trial Evaluating Imetelstat in Patients with Relapsed/Refractory Myelofibrosis
    Media name/outletHealth & Beauty Close-Up(Close-up Media)
    Country/TerritoryUnited States
    Date14/12/23
    PersonsJohn Mascarenhas
View all 1
View less